Michael Heike
Overview
Explore the profile of Michael Heike including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmitz C, Rekowski J, Muller S, Hertenstein B, Franzius C, Ganser A, et al.
Hematol Oncol
. 2020 Feb;
38(3):244-256.
PMID: 32067259
The prospective randomized Positron Emission Tomography (PET)-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) trial was designed to test the ability of interim PET (iPET) to direct therapy. As reported previously,...
2.
Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, et al.
Lancet
. 2019 Apr;
393(10184):1948-1957.
PMID: 30982686
Background: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and...
3.
Schimanski C, Staib F, Gohler T, Hebart H, Heike M, Neise M, et al.
J Cancer Res Clin Oncol
. 2017 Feb;
143(6):1023-1034.
PMID: 28197787
Purpose: Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al., Lancet Oncol 15(10):1065-1075, 2014; Van Cutsem et al. J Clin Oncol 27(19):3117-25; 2009b). Survival, response, and toxicity...
4.
Al-Batran S, Hofheinz R, Pauligk C, Kopp H, Haag G, Luley K, et al.
Lancet Oncol
. 2016 Oct;
17(12):1697-1708.
PMID: 27776843
Background: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma, but has not yet been evaluated in the context of resectable patients. Here we report findings from the...
5.
Farnik H, Driller M, Kratt T, Schmidt C, Fahndrich M, Filmann N, et al.
PLoS One
. 2015 Jan;
10(1):e0117483.
PMID: 25629619
Background: Intestinal perforation or leakage increases morbidity and mortality of surgical and endoscopic interventions. We identified criteria for use of full-covered, extractable self-expanding metal stents (cSEMS) vs. 'Over the scope'-clips...
6.
Fahndrich M, Heike M, Sandmann M
Endoscopy
. 2014 Oct;
46 Suppl 1 UCTN:E466.
PMID: 25314198
No abstract available.
7.
Faehndrich M, Heike M, Sandmann M
Endoscopy
. 2014 Oct;
46 Suppl 1 UCTN:E424.
PMID: 25314175
No abstract available.
8.
Schimanski C, Mohler M, Schon M, Van Cutsem E, Greil R, Bechstein W, et al.
BMC Cancer
. 2012 Apr;
12:144.
PMID: 22494623
Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver...
9.
Moehler M, Zeidler M, Wilsberg V, Cornelis J, Woelfel T, Rommelaere J, et al.
Hum Gene Ther
. 2005 Aug;
16(8):996-1005.
PMID: 16076257
Oncotropic and oncolytic viruses have attracted high attention as antitumor agents because they preferentially kill cancer cells in vitro and reduce the incidence of spontaneous, induced, or implanted animal tumors....
10.
Teufel A, Steinmann S, Siebler J, Zanke C, Hohl H, Adami B, et al.
BMC Cancer
. 2004 Jul;
4:38.
PMID: 15265233
Background: Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer. However, in light of safety...